Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06445439 · ClinicalTrials.gov registry record · NA
Optimal Pacing Rate for Cardiac Resynchronization Therapy
A NA study of Atrial Fibrillation, Persistent, sponsored by Medstar Health Research Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 60
- Enrollment target
- 5
- Study locations
NCT06445439: Recruiting NA study of Atrial Fibrillation, Persistent, sponsored by Medstar Health Research Institute.
NCT06445439 is a NA study of Atrial Fibrillation, Persistent that is actively recruiting participants, run by Medstar Health Research Institute. The registered enrollment target is 60 participants, below the 192-participant average among 3 other Atrial Fibrillation, Persistent trials with a reported enrollment target (69% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06445439, a NA study of Atrial Fibrillation, Persistent, is actively recruiting participants, sponsored by Medstar Health Research Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a prospective, randomized crossover study. The objective of the study is to determine if a pacing rate of 80 beats per minute (bpm) improves exercise tolerance during the 6-minute walk test. The investigators will randomly assign half of the participants to a starting rate of 60 bpm and then switch them to a rate of 80 bpm for 3 months, and vice versa.
Conditions Studied
Interventions
- DEVICE Pacing rate of 80 bpm
- DEVICE Pacing rate of 60 bpm
Study Locations (5)
District of Columbia
- MedStar Georgetown University Hospital - Washington D.C.
- MedStar Washington Hospital Center - Washington D.C.
Maryland
- MedStar Union Memorial Hospital - Baltimore
- MedStar Southern Maryland Hospital - Clinton
Virginia
- MedStar Heart and Vascular Office at Fairfax - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-12-19 |
| Est. Completion | 2025-08 |
| Phase | NA |
What NCT06445439 shows while recruiting
NCT06445439 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 192-participant average among 3 other Atrial Fibrillation, Persistent trials with a reported enrollment target (69% lower).
The record links to 1 condition, with Atrial Fibrillation, Persistent appearing as the primary indexed condition, and to 2 interventions - of which Pacing rate of 80 bpm is the first listed.
NCT06445439 lists 5 locations in 3 states (District of Columbia, Maryland, Virginia).
Frequently Asked Questions
What is clinical trial NCT06445439 about?
NCT06445439 is a clinical study titled "Optimal Pacing Rate for Cardiac Resynchronization Therapy". This is a prospective, randomized crossover study. The objective of the study is to determine if a pacing rate of 80 beats per minute (bpm) improves exercise tolerance during the 6-minute walk test. The investigators will randomly assign half of the participants to a starting rate of 60 bpm and then...
What is the current status of trial NCT06445439?
This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2023-12-19. Estimated completion is 2025-08.
What conditions does trial NCT06445439 study?
This clinical trial studies the following conditions: Atrial Fibrillation, Persistent.
What interventions are being tested in trial NCT06445439?
The interventions under investigation include: Pacing rate of 80 bpm (DEVICE), Pacing rate of 60 bpm (DEVICE).
Who is sponsoring clinical trial NCT06445439?
This trial is sponsored by Medstar Health Research Institute, which has 115 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06445439 being conducted?
This trial has 5 study locations across District of Columbia, Maryland, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation, Persistent
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
RESOLVE-AF: Clinical Evaluation of the Ablacath™ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-PV Sources of Atrial Fibrillation and Guide Ablation Therapy.
ACTIVE NOT RECRUITING · NA
-
Assert-IQ Implantable Cardiac Monitor (ICM) Post Market Study
ACTIVE NOT RECRUITING
-
AF-FLOW Registry to Evaluate Electrographic Flow Mapping in Patients Undergoing Ablation for Atrial Fibrillation
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI